{"id":"tp-55722","type":"article-newspaper","title":"Aktis Oncology’s Q3 Net Loss Nearly Doubles to $29.9 Million","author":"John Kim","publisher":"TOKENPOST Inc.","url":"https://www.tokenpost.com/news/business/55722","datePublished":"2026-11-12T17:55:25.000Z","dateModified":"2026-11-12T17:55:25.000Z","language":"en","abstract":"Research and development expenses rose to $32.1 million as the company began a third Phase 1b trial and expects its cash to fund operations into 2029.","section":"Business","references":[]}